KPKrisna Tsaniadi Prihastomo

Krisna Tsaniadi Prihastomo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Krisna Tsaniadi Prihastomo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The survival benefits of adjuvant radiotherapy for malignant meningioma: a retrospective cohort study

    by Yuriz Bakhtiar, Fariz Eka Setiawan, Rafi Ilmansyah, Krisna Tsaniadi Prihastomo, Dody Priambada, Faiza Rizky Aryani Septarina, Muhamad Thohar Arifin, Zainal Muttaqin

    BackgroundMalignant meningiomas (MM) are rare aggressive tumors associated with poor survival outcomes. Due to their rarity, there is limited data on the outcomes and prognostic factors of MM patients, particularly on adjuvant radiotherapy roles in this tumor population. This study aims to investigate the clinical characteristics, prognostic factors, and survival outcomes of MM with focus on survival benefits of adjuvant radiotherapy. MethodsThis retrospective cohort study analyzed 19 MM patients, who were initially subjected to postoperative radiotherapy, at Dr. Kariadi General Hospital, Semarang, from 2013 to 2023. Kaplan-Meier analysis was used to estimate survival rates at 1, 2, and 5 years. Univariate and multivariate Cox regression analyses were performed to identify factors associated with overall survival (OS). Variables with a p-value ≤ 0.25 in univariate analysis were included in the multivariate models. ResultsThe median OS was 16 months (95% CI 0.0–40.2), with estimated 1-year, 2-year, and 5-year survival rates of 52.6%, 42.1%, and 15.8%, respectively. Adjuvant radiotherapy (RDT) was associated with a significantly improved OS (p<0.001). However, sex, age, tumor location, and extent of resection did not show a significant association with OS. Cox regression showed that RDT had no statistically significant effect on OS in the multivariate model (HR = 0, 95% CI 0–1.8, p=0.923). ConclusionAdjuvant radiotherapy is critical for improving OS in MM patients, and gross-total resection (GTR) alone does not guarantee better long-term outcomes. Further studies with larger cohorts and molecular analysis are necessary to refine treatment strategies for MM.


  • Do Haematological Laboratory Data Associate with Tumour Size, Cavernous Sinus Invasion, and Sellar Erosion in Patients with Pituitary Adenoma?

    by Yuriz Bakhtiar, Edwin Sugondo Taufik, Irfan Kesumayadi, Rafi Ilmansyah, Adrian Pratama, Dody Priambada, Krisna Tsaniadi Prihastomo, Muhamad Thohar Arifin

    Background: Pituitary adenomas (PAs) are the most prevalent neuroendocrine tumour. Inflammation, both within the tumour microenvironment and systemically, plays a role in tumour biology. Haematological laboratory data serves as an initial and cost-effective approach. This study explores the association between haematological indices (e.g., NLR, PLR, LMR) and PA characteristics (tumour size, sellar erosion, cavernous sinus invasion). Methods: A retrospective study (2018–January 2023) analysed preoperative haematological data (such as neutrophil to lymphocyte ratio [NLR], platelet to lymphocyte ratio [PLR], and lymphocyte to monocyte ratio [LMR]) from PA patients. The haematological data was analysed based on tumour characteristic with p 0.05 considered significant. Results: Among 64 patients (mean age 45.55±14.67), 20–40% had elevated NLR, PLR, and LMR. Tumour characteristics included 60.9% macroadenomas and 39.1% giant PAs, with 43.8% showing sellar erosion and 42.2% cavernous sinus invasion. Monocyte counts were significantly higher in giant PAs vs. macroadenomas (7.48 ± 1.91 vs. 6.49 ± 1.95, p=0.040), and platelet counts were higher in sellar erosion vs. enlargement (336,710 ± 90,460 vs. 284,720 ± 89,766, p=0.016). Conclusion: Our study found that patients with giant PAs had significantly higher monocyte counts.

  • Open Access

    Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients

    by Dody Priambada, Muhamad Thohar Arifin, Abdi Saputro, Azka Muzakka, Vega Karlowee, Udadi Sadhana, Yuriz Bakhtiar, Krisna Tsaniadi Prihastomo, Ajid Risdianto, Happy Kurnia Brotoarianto, et al.

    Background: The current World Health Organization (WHO) 2021 classification of human glioma is based on key molecular biomarkers to define neoplastic entities. This review further delineates mutant IDH (isocitrate dehydrogenase) from wild-type IDH disease, a necessity given the large survival gap between mutant IDH and wild-type IDH tumors. In Indonesia, there are currently few reports on the distribution and significance of these mutations. Therefore, this research aims to determine the relationship between IDH mutations, as well as clinicopathological and prognostic factors in patients with gliomas. Other immunohistochemical markers including ATRX (alpha-thalassemia/mental retardation, X-linked), Ki67 and GFAP (glial fibrillary acidic protein) expression were also evaluated. Methods: Forty-two glioma samples were collected from patients who underwent surgery at Dr. Kariadi General Hospital in Semarang, Central Java, Indonesia. Fresh and paraffin-embedded, formalin-fixed tissue samples were removed and sectioned for hematoxylin and eosin staining, immunohistochemistry, and IDH analysis of mutation. Medical records were used to collect clinicopathological and survival data. Results: IDH1 mutations were discovered in 32 (76,1%) patients, and those with IDH1 mutation had longer overall survival when corresponded to patients with IDH1-wild-type. Lower expression of Ki67 was discovered to be very associated with a better prognosis. Conclusion: IDH1 mutations status showed a significant relationship with prognosis in patients with glioma. Meanwhile, other markers (ATRX, Ki67, and GFAP) did not correlate with the prognosis.